As expectations for refractive cataract surgery continue to rise, preoperative ocular surface optimization remains essential ...
Advanced disease progression occurred less often with vutrisiran than placebo in both the overall population (8.0% vs 10.7%) and monotherapy subgroup (8.2% vs 11.1%). Transition to NYHA class IV was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results